Login to Your Account

Clinic Roundup

Wednesday, July 31, 2013
• Immunocellular Therapeutics Ltd., of Los Angeles, said it started a Phase I trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription